What we know
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Sentences the outlets themselves published, word for word, each with its source. Banana News does not write or summarise.
What we know
- While GLP-1 medications like Ozempic, Wegovy and Zepbound have reshaped weight management and diabetes control, research shows that many patients stop taking them within a year. — New York Post New
- A physician outlines six risks, from weight regain and muscle loss to worsening biomarkers and mental health consequences. — Fox News
How each outlet words the headline
- Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns — Fox News · 13:00 UTC
- GLP-1 users face 6 rebound risks after stopping the weight-loss drugs — New York Post · 21:17 UTC
How this works
Every sentence above is copied word for word from the short snippet an outlet published in its own feed, and links to that outlet. We only choose which sentences to show and group the ones that match. Nothing is generated, translated or summarised, so it may be incomplete. Always read the original.